Hepion Pharmaceuticals appoints James Liddy as director effective August 19, 2026

Hepion Pharmaceuticals, Inc.

Board approved James Liddy as director on August 19, 2026, effective immediately.
No arrangements or understandings exist with any person regarding Liddy's selection.
No transactions involving Hepion and Liddy required under Item 404(a) of Reg S-K.
Form signed by interim CEO Gary Stetz on August 20, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.